Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy

Neoplasia(2022)10.1016/j.neo.2022.100824Source: DataRank Database

Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy is a research paper published in Neoplasia (2022). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 1.19)OA: goldTopics (44)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Shankar Suman ORCID,Joseph M. Amann,Ruohan Wu ORCID,David P. Carbone ORCID,Jie Wang ORCID

Live enrichment

PubMed:35914370 PMC:PMC9344351 OpenAlex:https://openalex.org/W4288901792

National Natural Science Foundation of China

Grant: 81630071

National Natural Science Foundation of China

Grant: 81871889

National Natural Science Foundation of China

Grant: 81972905

National Key Research and Development Program of China

Grant: 2019YFC1315700

National Institutes of Health

Grant: R01 CA175370

National Institutes of Health

Grant: R01 CA248741

NCI NIH HHS

Grant: T32 CA090223

National Institutes of Health

Grant: 5R01CA248741-04

Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer

National Institutes of Health

Grant: 5R01CA175370-05

Notch ligands in regulation of anti-cancer immunity

Ohio State University

FWCI

1.19

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://www.sciencedirect.com/science/article/pii/S1476558622000513/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S1476558622000513/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1476558622000513?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1476558622000513?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.neo.2022.100824

Fields of Study

Adenosine and Purinergic SignalingImmune cells in cancerPhagocytosis and Immune Regulation0301 basic medicine0303 health sciences03 medical and health sciencesAdenosineAnimalsCarcinoma, Non-Small-Cell LungLung NeoplasmsReceptor, Adenosine A2AReceptor, Adenosine A2BTumor Microenvironment

MeSH Terms

AdenosineAnimalsCarcinoma, Non-Small-Cell LungLung NeoplasmsReceptor, Adenosine A2BReceptor, Adenosine A2ATumor Microenvironment

Keywords

MedicineImmune systemAdenosineTumor microenvironmentCancer researchAdenosine receptorAdenosine A2A receptorReceptorImmunologyBiologyInternal medicineGene mutationMetabolismNon-small cell lung cancerA2ar/a2br AntagonistTumor And Immune CellsLung NeoplasmsReceptor, Adenosine A2ANeoplasms. Tumors. Oncology. Including cancer and carcinogensReceptor, Adenosine A2BCarcinoma, Non-Small-Cell LungAnimalsRC254-282Original Research

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Life below water

Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy

FAIR Checklist

Authors (7)

Funding (10 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)